UNSPSC 51432608: Naftopidil dihydrochloride

This classification denotes an antiplatelet agent and alpha-adrenergic blocking agent with the molecular formula C24H28N2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6I80E37JBE, chemically known as naftopidil dihydrochloride, (+/-)-, but more generally known as naftopidil dihydrochloride, which bears US NIH Compound Identifier 6603044. European Medicines Agency schedules naftopidil dihydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09132MIG.

Most nations, for tariff purposes, schedule naftopidil dihydrochloride under HS 29335995. SMILES: COC1CCCCC1N2CCN(CC2)CC(COC3CCCC4C3CCCC4)O.CL.CL.

UNSPSC 51432608 Naftopidil dihydrochloride is a Commodity code that covers pharmaceutical active ingredients and finished medications supplied to state and local healthcare systems, emergency services, and state health agency programs. Recent solicitations under this code show state and local governments purchasing advanced life support medications and generic pharmaceuticals through both direct procurement and cooperative purchasing arrangements. The City of Tampa's Fire Rescue department and the Texas Health and Human Services Commission represent the range of end-users acquiring medications under this code's scope—from municipal emergency medical services to state-level pharmacy benefit programs. Issuing bodies include municipal purchasing departments, state health agencies, and multistate cooperative purchasing alliances that aggregate demand across multiple state and local jurisdictions.

Activity centers in Florida, Texas, and Minnesota based on recent opportunities. The City of Tampa issued an IFB (Bid No. 26P00188) with a response date of April 8, 2026, for advanced life support medications including labetalol, epinephrine, adenosine, and diltiazem to supply Tampa Fire Rescue, with an estimated contract value of $40,000 and a one-year term renewable for two additional years, featuring a 5 percent Small Local Business Enterprise (SLBE) bid discount. The Texas Health and Human Services Commission posted a Request for Information (RFI) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling future formal procurement activity. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP with a response date of March 26, 2026, to establish multiple-award contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local government facilities in Minnesota and Oregon, with contract effective date July 1, 2026, and a two-year term. Vendors supplying under this code must comply with FDA requirements, current Good Manufacturing Practices (cGMP), Drug Supply Chain Security Act (DSCSA) certification, and OSHA Hazard Communication Standards.